Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1962 2
1965 1
1968 4
1969 2
1970 3
1971 1
1972 6
1973 4
1974 1
1975 4
1976 1
1977 5
1978 1
1979 3
1980 3
1981 5
1982 6
1983 3
1984 8
1985 2
1986 3
1987 4
1988 11
1989 12
1990 11
1991 8
1992 12
1993 14
1994 20
1995 19
1996 28
1997 23
1998 30
1999 33
2000 29
2001 26
2002 26
2003 36
2004 23
2005 44
2006 31
2007 26
2008 31
2009 35
2010 25
2011 36
2012 53
2013 42
2014 46
2015 45
2016 50
2017 65
2018 70
2019 82
2020 73
2021 80
2022 47
2023 54
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

1,269 results

Results by year

Filters applied: . Clear all
Page 1
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Hihara M, Soeda J, Misumi T, Yamamoto K, Akagi K, Ochiai A, Uetake H, Tsuchihara K, Yoshino T. Watanabe J, et al. Among authors: yasui h. JAMA. 2023 Apr 18;329(15):1271-1282. doi: 10.1001/jama.2023.4428. JAMA. 2023. PMID: 37071094 Free PMC article. Clinical Trial.
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Kang YK, et al. Among authors: yasui h. Lancet Oncol. 2022 Feb;23(2):234-247. doi: 10.1016/S1470-2045(21)00692-6. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030335 Clinical Trial.
Response.
Hozumi H, Kono M, Hasegawa H, Yasui H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Inui N, Nakamura Y, Yokomura K, Nakamura H, Suda T. Hozumi H, et al. Among authors: yasui h. Chest. 2021 Dec;160(6):e683-e685. doi: 10.1016/j.chest.2021.07.044. Chest. 2021. PMID: 34872693 No abstract available.
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590.
Kojima T, Hara H, Tsuji A, Yasui H, Muro K, Satoh T, Ogata T, Ishihara R, Goto M, Baba H, Nishina T, Han S, Sakata T, Yatsuzuka N, Doi T, Kato K. Kojima T, et al. Among authors: yasui h. Esophagus. 2022 Oct;19(4):683-692. doi: 10.1007/s10388-022-00920-x. Epub 2022 Jun 7. Esophagus. 2022. PMID: 35668304 Free PMC article. Clinical Trial.
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.
Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, Esaki T, Komatsu Y, Kawamoto Y, Takahashi N, Ueno M, Kagawa Y, Nishina T, Kato T, Yamamoto Y, Furuse J, Denda T, Kawakami H, Oki E, Nakajima T, Nishida N, Yamaguchi K, Yasui H, Goto M, Matsuhashi N, Ohtsubo K, Yamazaki K, Tsuji A, Okamoto W, Tsuchihara K, Yamanaka T, Miki I, Sakamoto Y, Ichiki H, Hata M, Yamashita R, Ohtsu A, Odegaard JI, Yoshino T. Nakamura Y, et al. Among authors: yasui h. Nat Med. 2020 Dec;26(12):1859-1864. doi: 10.1038/s41591-020-1063-5. Epub 2020 Oct 5. Nat Med. 2020. PMID: 33020649 Clinical Trial.
A predictive model for acute exacerbation of idiopathic interstitial pneumonias.
Karayama M, Aoshima Y, Suzuki T, Mori K, Yoshizawa N, Ichikawa S, Kato S, Yokomura K, Kono M, Hashimoto D, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Goshima S, Inui N, Suda T. Karayama M, et al. Among authors: yasui h. Eur Respir J. 2023 May 5;61(5):2201634. doi: 10.1183/13993003.01634-2022. Print 2023 May. Eur Respir J. 2023. PMID: 36822633 Free PMC article.
Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: A randomized, open-label trial.
Fujisawa T, Hozumi H, Kamiya Y, Kaida Y, Akamatsu T, Kusagaya H, Satake Y, Mori K, Mikamo M, Matsuda H, Yokomura K, Koshimizu N, Toyoshima M, Imokawa S, Yasui H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T. Fujisawa T, et al. Among authors: yasui h. Respirology. 2021 Apr;26(4):370-377. doi: 10.1111/resp.13978. Epub 2020 Nov 11. Respirology. 2021. PMID: 33179395 Free article. Clinical Trial.
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Dib Bartolomeo M, Lonardi S, Tabernero J, Van Cutsem E, Janjigian YY, Oh DY, Xu J, Fang X, Shih CS, Bhagia P, Bang YJ; KEYNOTE-585 investigators. Shitara K, et al. Among authors: yasui h. Lancet Oncol. 2024 Feb;25(2):212-224. doi: 10.1016/S1470-2045(23)00541-7. Epub 2023 Dec 19. Lancet Oncol. 2024. PMID: 38134948 Clinical Trial.
Total Synthesis of Clavilactones.
Takao KI, Mori K, Kasuga K, Nanamiya R, Namba A, Fukushima Y, Nemoto R, Mogi T, Yasui H, Ogura A, Yoshida K, Tadano KI. Takao KI, et al. Among authors: yasui h. J Org Chem. 2018 Jul 6;83(13):7060-7075. doi: 10.1021/acs.joc.7b03268. Epub 2018 Feb 5. J Org Chem. 2018. PMID: 29383938
Molecularly-targeted therapy for the oral cancer stem cells.
Ohnishi Y, Yasui H, Nozaki M, Nakajima M. Ohnishi Y, et al. Among authors: yasui h. Jpn Dent Sci Rev. 2018 May;54(2):88-103. doi: 10.1016/j.jdsr.2017.11.001. Epub 2017 Dec 16. Jpn Dent Sci Rev. 2018. PMID: 29755619 Free PMC article. Review.
1,269 results